ATHJF Stock UPDATES Antisense Therap Ltd (ATHJF) 0.1390 08/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Antisense Therap Ltd (ATHJF) 0.1390 $ATHJF

ATL1103 Acromegaly Phase II Trial Dosing Completed
PR Newswire - Tue Jul 29, 7:00AM CDT
Antisense Therapeutics Limited ("ANP" is pleased to report that dosing of all 26 patients in the Phase II trial of ATL1103 for the potentially life-threatening growth disorder, acromegaly has now been completed. There were no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103. Patients will continue to be monitored for a period of two months after their last dose of ATL1103.

Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014
M2 - Tue Jun 10, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dl3fhl/hematopoietic) has announced the addition of the "Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Companies Mentioned: - Hospira, Inc. - Athersys, Inc. - GlaxoSmithKline plc - BioLineRx, Ltd. - Novartis AG - Celldex Therapeutics, Inc. - Antisense Therapeutics Limited - Actinium Pharmaceuticals, Inc. - Pharmalink AB - Recoly N.V. - Polyphor Ltd. - Kiadis Pharma B.V. - Bellicum Pharmaceuticals, Inc. - TaiGen Biotechnology Co., Ltd. - TikoMed AB - Tarix Pharmaceuticals LTD. For more information visit http://www.researchandmarkets.com/research/dl...atopoietic

ATL1102 for MS - Toxicology Study Main Findings
PR Newswire - Tue Apr 01, 8:45AM CDT
Antisense Therapeutics Limited ("ANP" or the "Company" is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). The Company believes that the preclinical and clinical experience to date with ATL1102 should allow dosing in future trials at or above the 1.5 mg/kg/dose level.

ATL1103 Acromegaly Phase II Trial Recruitment Completed
PR Newswire - Fri Mar 21, 9:00AM CDT
Antisense Therapeutics Limited ("ANP" is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial.

ATL1102 for Stem Cell Mobilisation Trial Commencement
PR Newswire - Mon Mar 17, 6:20PM CDT
Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).

Antisense Therapeutics Selected to Present at Biotech Showcase(TM) 2014
PR Newswire - Tue Jan 07, 4:49PM CST
Antisense Therapeutics Limited ("ANP" or "the Company" is pleased to advise that it has been selected to present at the Biotech Showcase 2014 conference to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA. This is a significant opportunity for ANP to present to and engage with distinguished US-based investors, prospective partners, and key industry leaders, and in particular discuss the successful progress of the company's Phase II acromegaly trial for ATL1103.

Positive Results Achieved from Interim Analysis of ATL1103 Phase II Trial
PR Newswire - Mon Dec 23, 6:15AM CST
Antisense Therapeutics Limited ("ANP" or "the Company" is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.

ANP to present at and attend major US investment, partnering and industry conferences
PR Newswire - Wed Aug 28, 6:30AM CDT
Antisense Therapeutics Limited (ASX:ANP) is pleased to advise that its Chief Executive Officer and Managing Director, Mark Diamond has been invited to present at two major investment and partnering focused conferences in the US, and will also attend an industry seminar on orphan drugs and rare diseases as the Company steps up its planning on its drug ATL1103 for acromegaly.

Bio-Path Holdings' Liposomal Delivery Technology Achieves Major Milestone in Development of Antisense Therapeutics
Business Wire - Fri Aug 09, 8:30AM CDT
Bio-Path Holdings, Inc. (OTCQX: BPTH) ("Bio-Path" , a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that a scientific assay has confirmed that its lead product candidate BP-100-1.01 (Liposomal Grb-2) inhibits the disease-causing target protein in patients with blood cancers. The assay was applied to patient samples taken from Bio-Path's Phase I clinical trial which is evaluating Liposomal Grb-2 in blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS). This discovery is a significant milestone in the development of Bio-Path's liposomal delivery technology and the specific data from this testing is planned to be reviewed at the Annual Society of Hematology (ASH) meeting in December by Jorge Cortes, M.D., Professor and Deputy Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center).




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global-E Faces Fresh Scrutiny After Muted Quarterly Outlook

Updated Category News Views 28

A guidance bump that barely clears the curb can still wreck a stock. That is the unpleasant read-through from Global-E Online's third-quarter 2026 report: revenue guidance went higher, but not high enough to persuade investors that the business was pulling away from expectations. Shares fell after the release, and a securities-law investigation announced November 19 has...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 57

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Jeff Stern Turns Travel Photography Into a Sensory Memoir

Updated Category News Views 68

Frost in a mountain tent, fermented mare’s milk in a yurt, and coffee in Vietnamese rice paddies are doing more work here than a thousand polished sunset captions ever could. Jeff Stern’s A Change of Scenery, released by Palmetto Publishing on November 17, 2026, comes from a man who spent more than 25 years building brands and then decided the usual labels around...

Continue Reading
Wenge AI Removes a Small Friction Point for ScienceOra

Updated Category News Views 77

Scientific software rarely loses users because the underlying model is too clever; it loses them because getting through the front door is a nuisance. Wenge AI has addressed that unglamorous problem by adding Google and Apple sign-in options to the international version of ScienceOra, its AI-powered research and decision-support platform. This is not the sort of...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 84

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 50

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 133

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading
AIC Hotel Group's 11 Awards Test Resort Market Reach

Updated Category News Views 89

Eleven Trophies, Four Properties, One Useful Signal Hospitality awards can be a lot of polished brass and very little cash flow, but this batch is substantial enough to deserve a hard look. AIC Hotel Group collected 11 honors spanning Condé Nast Traveler's 2026 Readers' Choice Awards, Travel Weekly's 2026 Magellan Awards, and Good Housekeeping's 2027 Travel Awards. The...

Continue Reading
Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 107

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading

Top 5 Most Recently Viewed Articles

Rob Shields Steps Up as Chief Growth Officer at Greenlane

Updated Category News Views 533

Greenlane Welcomes Rob Shields as Chief Growth Officer Greenlane Holdings, Inc. (NASDAQ: GNLN), a distributor of premium cannabis accessories and vaporization products, has recently appointed Rob Shields as Chief Growth Officer. This transition comes at a pivotal time for the company, as it aims to enhance its market presence and address ongoing challenges in the...

Continue Reading
HealthBird Revolutionizes Healthcare in Ecuador with Collaboration

Updated Category News Views 436

HealthBird Partners with Ecuador to Innovate Healthcare HealthBird, a leading health technology provider, is making waves as it spearheads an innovative healthcare initiative in Ecuador. The company, associated with OneNest, aims to support the nation in transforming its healthcare system into a modern, efficient, and sustainable framework. With a commitment to investing...

Continue Reading
Exciting New Travelzoo Offers for Enthusiasts Awaiting You

Updated Category News Views 579

Exciting Travel Offers for Members Travelzoo® (NASDAQ: TZOO), a renowned name for travel enthusiasts, has recently unveiled new Club Offers designed specifically for its members. These unique deals have been meticulously vetted and negotiated to ensure travelers can enjoy exceptional experiences at remarkable prices. Explore Enchanting Destinations Among the latest...

Continue Reading
Join Tiptree for Insights on Q3 2024 Performance

Updated Category News Views 180

Join Tiptree for Insights on Q3 2024 Performance Tiptree Inc. (NASDAQ:TIPT) is gearing up for an engaging conference call and live webcast to delve into the details of its Q3 2024 results. Scheduled for Thursday, October 31, 2024, at 10:30 AM ET, this event promises to be an informative session for all stakeholders. How to Access the Conference Call Participants wishing...

Continue Reading
WOW! Expands Services in Florida with New Fiber Customers

Updated Category News Views 236

WOW! Expands Its Fiber Network in Florida Residents and businesses can now eagerly sign up for WOW!'s all-fiber services that come with simplified pricing, marking a significant milestone in the company's expansion efforts within the state. Enhanced Connectivity for Communities WOW! Internet, TV & Phone (NYSE: WOW), renowned for its reliable broadband services, has...

Continue Reading